Please use this identifier to cite or link to this item:
https://doi.org/10.3390/ijms22031141
DC Field | Value | |
---|---|---|
dc.title | Artemether-loaded zein nanoparticles: An innovative intravenous dosage form for the management of severe malaria | |
dc.contributor.author | Boateng-Marfo, Yaa | |
dc.contributor.author | Dong, Yuancai | |
dc.contributor.author | Ng, Wai Kiong | |
dc.contributor.author | Lin, Hai-Shu | |
dc.date.accessioned | 2022-10-11T08:03:48Z | |
dc.date.available | 2022-10-11T08:03:48Z | |
dc.date.issued | 2021-01-24 | |
dc.identifier.citation | Boateng-Marfo, Yaa, Dong, Yuancai, Ng, Wai Kiong, Lin, Hai-Shu (2021-01-24). Artemether-loaded zein nanoparticles: An innovative intravenous dosage form for the management of severe malaria. International Journal of Molecular Sciences 22 (3) : 1-22. ScholarBank@NUS Repository. https://doi.org/10.3390/ijms22031141 | |
dc.identifier.issn | 1661-6596 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/232146 | |
dc.description.abstract | Artemether, an artemisinin derivative, is used in the management of life-threatening severe malaria. This study aimed to develop an intravenous dosage form of artemether using nanotechnology. Artemether-loaded zein nanoparticles were prepared by modified antisolvent precipitation using sodium caseinate as a stabilizer. Subsequently, the physicochemical properties of the nanoparticles were characterized; the in vitro hemolytic property was examined with red blood cells, while the pharmacokinetic profile was evaluated in Sprague–Dawley rats after intravenous administration. The artemether-loaded zein nanoparticles were found to display good encapsulation efficiency, excellent physical stability and offer an in vitro extended-release property. Interestingly, encapsulation of artemether into zein nanoparticles substantially suppressed hemolysis, a common clinical phenomenon occurring after artemisinin-based antimalarial therapy. Upon intravenous administration, artemether-loaded zein nanoparticles extended the mean residence time of artemether by ~80% in comparison to the free artemether formulation (82.9 ± 15.2 versus 45.6 ± 16.4 min, p < 0.01), suggesting that the nanoparticles may prolong the therapeutic duration and reduce the dosing frequency in a clinical setting. In conclusion, intravenous delivery of artemether by artemetherloaded zein nanoparticles appears to be a promising therapeutic option for severe malaria. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.publisher | MDPI AG | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2021 | |
dc.subject | Artemether | |
dc.subject | Artemisinin | |
dc.subject | Extended release | |
dc.subject | Hemolysis | |
dc.subject | Intravenous | |
dc.subject | Nanoparticles | |
dc.subject | Pharmacokinetics | |
dc.subject | Severe malaria | |
dc.subject | Sodium caseinate | |
dc.subject | Zein | |
dc.type | Article | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.3390/ijms22031141 | |
dc.description.sourcetitle | International Journal of Molecular Sciences | |
dc.description.volume | 22 | |
dc.description.issue | 3 | |
dc.description.page | 1-22 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_ijms22031141.pdf | 3.63 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License